Investor relations

Investor relations

Investor Menu

Developing transformative therapies targeting cancer

Seagen is a global, multi-product biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people’s lives. We are commercializing ADCETRIS® for the treatment of several types of CD30-expressing lymphomas, PADCEV® for the treatment of locally advanced or metastatic urothelial cancer, TUKYSA® for the treatment of certain HER2-positive metastatic breast cancers, and TIVDAK® for recurrent or metastatic cervical cancer. We are also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Many of our programs, including ADCETRIS, PADCEV and TIVDAK, are based on our proprietary antibody-drug conjugate, or ADC, technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

Recent news

View all news
View all quarters